Eurofins Worldwide
Careers at Eurofins
Find here the projects we sponsor
Download pdf of the Executive Summary
Eurofins Scientific is a life sciences company operating laboratories in 29 countries to provide a comprehensive range of analytical testing services drawing on the latest developments in biotechnology. The Group specialises in delivering analytical testing and advisory services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. With about $ 800 million in annual sales, Eurofins believes it is the global leader in food testing, belongs to the leading global laboratory groups serving the pharmaceutical industry and is number one in Europe in the environmental testing field.
Eurofins Scientific was founded in 1987 to market the SNIF-NMR technology, a patented analytical method used to verify the origin and purity of several types of food and beverages in cases where traditional testing methods would fail to detect a sophisticated fraud. Within a 20-year period, the Group has grown from a start-up company with 12 employees to become an international network of over 150 laboratories located in Europe, the USA, Asia and South-America employing about 7,000 staff. With a portfolio of over 25,000 reliable analytical methods and performing more than 80 million assays per year to establish the safety, composition, authenticity, origin, traceability, identity and purity of biological substances, the Eurofins Group is now a leading global provider of bioanalytical services.
Eurofins is one of the fastest growing companies in Europe: since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by more than 50% each year (in compound average) to € 492 m in 2007. The shares of Eurofins Scientific are traded on NYSE Euronext Paris and Deutsche Börse/XETRA (Frankfurt). Eurofins belongs to the following indices: NYSE Euronext SBF 250, MidCAC 100, Next150, SRD and Compartiment A and thus ranks amongst the largest 250 companies listed in Paris, Amsterdam, Brussels and Lisbon.
The Group has recently invested significantly in its aim to achieve global market leadership. It invested in organic growth with the entry into 4 new countries (Slovakia, Finland, Hungary and Bulgaria), the strengthening of its recent established areas (China, Singapore, Sweden, Poland, Italy and Spain), the consolidation of existing facilities in many countries (e.g. Paris and Saverne in France, Munich in Germany, Heerenveen in the Netherlands, Des Moines in the US), the redevelopment or construction of laboratories to the highest standards (Singapore, Acton, Colorado) and the ongoing rolling out of IT systems for laboratory management and Group-wide marketing (COMLims and eLIMS). The Group made two large acquisitions at the end of 2007 with Analycen in Scandinavia and the genomics company Operon in Germany, the US and Japan.
These activities enabled Eurofins to strengthen its position in the food and pharmaceutical testing sectors as well as in the field of DNA, genotyping and clinical trials. The Group has enhanced its offer to the pharmaceutical and biotechnological industries and now spans almost all of the product development cycle. The Group has become one of Europe’s largest Contract Research Organisations for the pharmaceutical, agro-pharmaceutical and biotechnological industries.
Eurofins has established several world-class Competence Centres and believes it is the global leader in the analysis for trace amounts of dioxins and Persistent Organic Pollutants as well as in testing for Genetically Modified Organisms (GMO). This structure, combined with a broad test portfolio and technical expertise has allowed the Group to react quickly to protect its clients from recent food and feed scares (e.g. food and feed contamination with veterinary residues, forbidden dyes, melamine and unauthorised GMO). Eurofins has developed many new analytical testing methods and has participated in or led several R&D projects in association with government bodies, industry and universities.
Eurofins intends to strengthen its global position as a leading bioanalysis laboratory group serving the pharmaceutical, food and environmental industries and aims to become a global market leader in this field of applied life sciences. To achieve this, the Group has set an ambitious revenue objective of €1 billion by 2011.
